Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S161-8. doi: 10.1586/14760584.3.4.s161.

Abstract

Genetic variation of HIV-1 represents a major obstacle for AIDS vaccine development. With the amino acid sequence divergence as high as 30% in envelopes between different subtypes among HIV-1 group M viruses, it is unlikely that cross-subtype protection will occur equally well among all subtypes. Computer programs have been used to generate 'centralized' HIV gene sequences: consensus, ancestor or center of the tree. These sequences can decrease the genetic distances between the 'centralized' and wild-type gene immunogens to half of those between any wild-type immuongens to each other. Recent studies demonstrated that an artificial group M consensus env gene is equidistant from any subtype and recombinants. It is biologically functional and preserves antigenicity similar to contemporary Env proteins. Most importantly, the group M consensus Env immunogen can elicit both T- and B-cell responses to wild-type HIV-1 isolates.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • AIDS Vaccines / immunology*
  • Amino Acid Sequence
  • Animals
  • Epitopes, B-Lymphocyte / immunology
  • Epitopes, T-Lymphocyte / immunology
  • Genetic Variation
  • Genome, Viral
  • HIV Antigens / genetics*
  • HIV Antigens / immunology*
  • HIV-1 / genetics*
  • HIV-1 / immunology*
  • Humans
  • Software

Substances

  • AIDS Vaccines
  • Epitopes, B-Lymphocyte
  • Epitopes, T-Lymphocyte
  • HIV Antigens